Security
CollPlant Biotechnologies Ltd Ordinary Shares · CLGN
CLGNNASDAQCommon stockCurrentCIK 1631487Updated Nov 6, 2026
Name history
CollPlant Biotechnologies Ltd. · through Jun 20, 2019CollPlant Holdings Ltd. · through Jun 6, 2019
CLGN price & chart
Loading TradingView…
NASDAQ:CLGN on TradingView ↗About the company
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. These products address indications for the diverse fields of tissue repair and aesthetics, and are ushering in a new era in regenerative and aesthetic medicine.
In the news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS News provided by CollPlant Nov 18, 2025, 07:00 ET Share this article Share to X Share this article Share to X REHOVOT, Israel , Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN ), a regenerative an ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 26,566,000Source | 41,569,000Source | 44,413,000Source | 55,020,000Source | 10,948,000Source | 9,547,000Source | 6,258,000Source | 10,785,000Source | 18,710,000Source | 34,126,000Source | 37,768,000Source |
| Property, Plant and Equipment, NetUSD | 2,561,000Source | 2,931,000Source | 2,925,000Source | 2,119,000Source | 2,248,000Source | — | — | 1,463,000Source | 2,290,000Source | 2,789,000Source | 2,966,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 159,000Source | 216,000Source | 235,000Source | 164,000Source | — | — | — | 73,000Source | 131,000Source | 188,000Source | 245,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,920,000Source | 22,283,000Source | 36,290,000Source | 17,485,000Source | 3,672,000Source | — | — | 5,591,000Source | 11,909,000Source | 26,674,000Source | 29,653,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 250,000Source | — | 9,000Source | 277,000Source | — | — | — | 1,000Source | 150,000Source | — | 9,000Source |
| Inventory, NetUSD | 439,000Source | 1,552,000Source | 1,356,000Source | 940,000Source | 730,000Source | — | — | 573,000Source | 440,000Source | 714,000Source | 1,430,000Source |
| Assets, CurrentUSD | 20,335,000Source | 34,858,000Source | 38,272,000Source | 49,767,000Source | 5,485,000Source | — | — | 6,747,000Source | 13,180,000Source | 28,022,000Source | 31,658,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 490,000Source | 758,000Source | 594,000Source | 979,000Source | 750,000Source | — | — | 223,000Source | 433,000Source | 393,000Source | 543,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,398,000Source | 3,327,000Source | 2,792,000Source | 2,792,000Source | 3,048,000Source | — | — | 2,426,000Source | 2,991,000Source | 3,070,000Source | 2,711,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 5,837,000Source | 5,530,000Source | 4,908,000Source | 5,582,000Source | 5,171,000Source | 7,719,000Source | 2,715,000Source | 4,704,000Source | 5,245,000Source | 5,786,000Source | 5,487,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 4,983,000Source | 4,963,000Source | 4,831,000Source | 4,448,000Source | 2,713,000Source | — | — | 5,492,000Source | 4,983,000Source | 4,982,000Source | 4,873,000Source |
| Retained Earnings (Accumulated Deficit)USD | -105,146,000Source | -87,675,000Source | -80,942,000Source | -65,948,000Source | -70,832,000Source | — | — | -124,839,000Source | -113,350,000Source | -96,741,000Source | -89,722,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -969,000Source | — | — | — | — | — | — | -969,000Source | -969,000Source | -969,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 20,729,000Source | 36,039,000Source | 39,505,000Source | 49,438,000Source | 5,777,000Source | 764,000Source | — | 6,081,000Source | 13,465,000Source | 28,340,000Source | 32,281,000Source |
| Additional Paid in Capital, Common StockUSD | 121,861,000Source | — | — | — | — | — | — | 126,397,000Source | 122,801,000Source | 121,068,000Source | — |
| Liabilities and EquityUSD | 26,566,000Source | 41,569,000Source | 44,413,000Source | 55,020,000Source | 10,948,000Source | — | — | 10,785,000Source | 18,710,000Source | 34,126,000Source | 37,768,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 3,241,000Source | 2,782,000Source | 2,361,000Source | 2,933,000Source | 2,176,000Source | — | — | 2,672,000Source | 2,970,000Source | 3,251,000Source | 3,105,000Source |
| Operating Lease, Liability, CurrentUSD | 789,000Source | 598,000Source | 477,000Source | 651,000Source | 442,000Source | — | — | 814,000Source | 806,000Source | 624,000Source | 529,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,596,000Source | 2,748,000Source | 2,547,000Source | 2,649,000Source | 2,953,000Source | — | — | 2,032,000Source | 2,275,000Source | 2,535,000Source | 2,382,000Source |
| Additional Paid in Capital | — | —Source | — | — | — | — | — | — | — | — | — |
| InvestmentProperty | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | -1,520,000Source | -1,549,000Source | — | — | — | -16,925,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 912,000Source | 1,038,000Source | 1,102,000Source | 1,036,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 999,000Source | 1,719,000Source | 1,937,000Source | — |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -149,000Source | 150,000Source | -9,000Source | -261,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | 129,000Source | -280,000Source | -749,000Source | 312,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | -9,419,000Source | -14,093,000Source | -2,763,000Source | -13,698,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -27,000Source | -539,000Source | -1,156,000Source | 28,922,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 28,000Source | 483,000Source | 954,000Source | 1,274,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 3,102,000Source | 9,000Source | 1,108,000Source | 1,874,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | -6,318,000Source | -14,765,000Source | -3,190,000Source | 16,490,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 18,920,000Source | 22,366,000Source | 36,502,000Source | 17,675,000Source | 3,851,000Source | 1,914,000Source | — | 5,591,000Source | 11,909,000Source | 26,674,000Source | — |
| Supplemental disclosure of cash flow information: | |||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 16,000Source | 62,000Source | 8,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | 26,000Source | -142,000Source | -379,000Source | -608,000Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | 490,000Source | 338,000Source | — | — | 477,000Source | 289,000Source | — | 1,003,000Source | 1,719,000Source | 1,937,000Source | — |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | — | — | — | — | — | — | 14,000,000Source | 14,000,000Source | 14,000,000Source | 14,000,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | 854,000Source | 981,000Source | 1,045,000Source | 1,076,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 87,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -18,000Source | — |
| General and Administrative ExpenseUSD | 1,422,000Source | 1,318,000Source | 1,609,000Source | 1,424,000Source | 986,000Source | 820,000Source | — | 4,832,000Source | 5,626,000Source | 5,996,000Source | 6,741,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 45,991,000Source | 59,993,000Source | — |
| Inventory Write-downUSD | — | 261,000Source | 6,000Source | 127,000Source | — | — | — | 133,000Source | 286,000Source | 866,000Source | 296,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | 380,000Source | 738,000Source | 788,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -4,210,000Source | 5,762,000Source | -4,285,000Source | -3,038,000Source | -1,971,000Source | -1,248,000Source | — | -11,489,000Source | -16,609,000Source | -7,019,000Source | -16,925,000Source |
| Nonoperating Income (Expense)USD | 196,000Source | 85,000Source | -100,000Source | — | — | — | — | -6,000Source | 642,000Source | 493,000Source | 172,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 20,000,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 249,000Source | 10,184,000Source | — | — | — | — | — | 2,371,000Source | 515,000Source | 10,959,000Source | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | —Source | —Source | — | — | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | 249,000Source | 10,184,000Source | 66,000Source | 691,000Source | 823,000Source | 606,000Source | 182,000Source | 201,000Source | 2,371,000Source | 515,000Source | 10,959,000Source | 299,000Source |
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | -4,406,000Source | 5,677,000Source | -4,185,000Source | -3,063,000Source | -1,913,000Source | -1,761,000Source | — | — | -11,483,000Source | -17,251,000Source | -7,512,000Source | -17,097,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 45,991,000Source | 59,993,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -4,210,000Source | 5,762,000Source | -4,285,000Source | -3,038,000Source | -1,971,000Source | -1,248,000Source | — | — | -11,489,000Source | -16,609,000Source | -7,019,000Source | -16,925,000Source |
| Earnings Per Share, BasicUSD per share | -0.37Source | 0.51Source | -0.39Source | -0.3Source | — | — | — | — | -0.94Source | -1.45Source | -0.62Source | -1.53Source |
| Earnings Per Share, DilutedUSD per share | -0.37Source | 0.49Source | -0.39Source | -0.3Source | — | — | — | — | -0.94Source | -1.45Source | -0.62Source | -1.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 11,454,512Source | 11,369,031Source | 11,086,481Source | 10,201,231Source | — | — | — | — | 12,203,269Source | 11,454,180Source | 11,389,168Source | 11,033,310Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 11,454,512Source | 11,777,139Source | 11,086,481Source | 10,201,231Source | — | — | — | — | 12,203,269Source | 11,454,180Source | 11,389,168Source | 11,033,310Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | 1,422,000Source | 1,318,000Source | 1,609,000Source | 1,424,000Source | 986,000Source | 820,000Source | — | — | 4,832,000Source | 5,626,000Source | 5,996,000Source | 6,741,000Source |
| Gross ProfitUSD | -287,000Source | 9,569,000Source | 23,000Source | 262,000Source | 75,000Source | 143,000Source | 115,000Source | 201,000Source | 1,536,000Source | -1,110,000Source | 8,968,000Source | -101,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 380,000Source | 738,000Source | 788,000Source | — |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | — | — | -172,000Source |
| Nonoperating Income (Expense)USD | 196,000Source | 85,000Source | -100,000Source | — | — | — | — | — | -6,000Source | 642,000Source | 493,000Source | 172,000Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | 11,000Source | 314,000Source | 523Source | — |
| Research and Development ExpenseUSD | 2,697,000Source | 2,574,000Source | 2,599,000Source | 1,901,000Source | 1,002,000Source | 1,084,000Source | 641,000Source | 4,298,000Source | 8,187,000Source | 10,515,000Source | 10,484,000Source | 10,255,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 249,000Source | 10,184,000Source | — | — | — | — | — | — | 2,371,000Source | 515,000Source | 10,959,000Source | — |
| Selling, General and Administrative Expense | — | — | — | — | — | —Source | —Source | —Source | — | — | — | — |
| FinanceCosts | — | — | — | — | — | —Source | —Source | —Source | — | — | — | — |
| FinanceIncome | — | — | — | — | — | —Source | —Source | — | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| ProfitLossFromOperatingActivities | — | — | — | — | — | —Source | —Source | —Source | — | — | — | — |
| Revenue | — | — | — | — | — | —Source | —Source | —Source | — | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | —Source | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-297347
Registration 333-294738
Registration 333-292640
Filing attachments
ea031104901ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU) Government-backed R&D program to advance next-generation LPU hardware and expand the LPU Lab platform | Builds on LightSolver’s recent commercial and technical momentum, including the strategic partnership with Boeing, peer-reviewed research with HLRS and a growing IP portfolio REHOVOT, Israel, November 5, 2026 -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) toda…
Read attachment ↗ea031088401ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light Proposed new identity reflects the Company’s strategic business expansion following its acquisition of LightSolver; change subject to shareholder approval Rehovot, Israel, November 4, 2026 -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its Board of Directors has approved a proposal to change the Company’s name to OptiPhi Computing Ltd., subject to shar…
Read attachment ↗ea031075201ex99-1.htm · 6-K · 2026-11-03
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday, November 24, 2026 The extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the “ Company ”) will be held at the offices of Goldfarb Gross Seligman & Co. at One Azrieli Center, Round Building, 40 th Floor, Tel-Aviv, Israel, on Tuesday, November 24, 2026, at 10:00 a.m. Israel time…
Read attachment ↗ea031075201ex99-2.htm · 6-K · 2026-11-03
Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record by the close of business on November 5, 2026 (the “ Record Date ”) of ordinary shares of CollPlant Biotechnologies Ltd. (the “ Company ”) are hereby notified of an upcoming extraordinary general meeting of the Company to be held on November 24, 2026 at 10:00 a.m. Israel time in Israel (the “ Meeting ”). Shareholders registered in the Company’s shareholders register may vote thr…
Read attachment ↗ea030994101ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 LightSolver Secures Paid Collaboration with the Israel Ministry of Defense for the Development of Photonic Computing Technology The Israel Ministry of Defense Engagement Strengthens LightSolver’s Position in the Emerging Photonic Computing Market for Defense Applications, Estimated at Up to $5 Billion Annually REHOVOT, Israel, October 29, 2026 - CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd. (“LightSolver”), a pioneer of pure ph…
Read attachment ↗ea030822201ex99-1.htm · 6-K · 2026-10-09
Exhibit 99.1 COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT Transaction Led Primarily by Existing Investors to Accelerate LightSolver’s Laser-Based Supercomputing Development REHOVOT, Israel, October 9, 2026 - CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Com…
Read attachment ↗